SYS6043 granted BTD in China for the treatment of platinum-resistant Ovarian cancer

CAR-T Digest - August 2020

Weekly Digest - July 2026

02 July 2026: SYS6043 granted BTD in China for the treatment of platinum-resistant Ovarian cancer

CSPC Pharmaceutical Group has received Breakthrough Therapy Designation from China’s NMPA for SYS6043, a B7-H3-targeted antibody-drug conjugate, for the treatment of platinum-resistant ovarian cancer, primary peritoneal carcinoma, and fallopian tube cancer, highlighting the potential of the asset to address a significant unmet need in advanced gynecologic malignancies
The designation was supported by clinical data demonstrating that SYS6043 delivered more durable anti-tumor activity and approximately doubled progression-free survival compared with non-platinum chemotherapy regimens and Mirvetuximab soravtansine, while maintaining a favorable overall safety profile in patients with platinum-resistant disease
The designation addresses a major unmet need in platinum-resistant ovarian cancer, where 70–80% of patients with advanced disease eventually relapse following platinum-based chemotherapy and available treatment options typically achieve objective response rates of only 10-15%, with limited durability and poor long-term outcomes
SYS6043 is a humanized B7-H3-targeted antibody-drug conjugate designed to selectively deliver cytotoxic therapy to B7-H3-expressing tumor cells. Beyond ovarian cancer, the ADC is also being evaluated in clinical studies across multiple solid tumors, including small cell lung cancer and breast cancer
Strategically, the Breakthrough Therapy Designation accelerates the development and regulatory pathway for SYS6043, strengthens CSPC’s position in the increasingly competitive B7-H3 ADC landscape, and reinforces the company’s broader ambition to build a differentiated oncology franchise through next-generation ADC innovation across multiple tumor types